KYMR
Kymera Therapeutics Inc
106.00$
-3.5%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -669.4% | 16.8% | -384.9% | -167.4% | -1,341.6% | -835.6% | -358.1% | -521.8% | -980.8% | -2,333.8% | -258.5% | -83.2% | -225.5% | |
| 18.9% | 1.9% | 14.2% | 7.6% | 53.1% | 26.9% | 9.3% | 18.2% | 77.7% | 71.0% | 5.9% | 3.1% | 7.8% | |
| 246.5% | 22.8% | 116.3% | 55.9% | 398.4% | 186.6% | 64.4% | 134.3% | 571.7% | 505.3% | 46.6% | 29.1% | 62.1% | |
| 207.6% | -1.1% | 18.1% | 42.0% | 36.4% | 46.0% | -123.6% | 11.8% | 1,392.1% | 202.6% | -101.6% | -17.7% | -2.0% | |
| 170.9% | 24.3% | 72.0% | 18.3% | 5.1% | 12.7% | 2.1% | 6.1% | 6.5% | 3.7% | 1.3% | 0.7% | 1.1% | |
| 1,279.8% | 39.6% | -3,213.8% | 61.0% | -4,214.9% | 927.3% | 220.0% | 523.0% | -8,513.0% | -13,790.1% | -415.7% | 30.8% | -716.7% | |
| – | – | – | – | -17.1% | -4.0% | -1.3% | -3.3% | -15.2% | -14.5% | -1.2% | -0.7% | -1.6% | |
| -4.4% | 4.0% | 3,438.9% | 5.5% | 6,707.2% | 37.4% | 1.2% | 2,141.2% | 1,429.5% | 24,658.0% | 54.6% | 22.2% | 741.0% | |
| 606.1% | 60.4% | -159.8% | -100.9% | 1,150.7% | 129.1% | -137.0% | 2,142.4% | -8,064.4% | 8,534.1% | -619.6% | -30.2% | -201.3% | |
| -840.2% | -7.5% | -456.8% | -185.7% | -1,336.6% | -848.3% | -360.3% | -527.9% | -987.4% | -2,337.5% | -259.8% | -83.9% | -226.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.